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Background:  This  study  was  designed  to evaluate  the prevalence  and  determinants  of  increased  high-
sensitivity  cardiac  troponin  T (hs-cTnT)  as  a marker  of cardiac  injury  in  patients  with  hypertrophic
cardiomyopathy  (HCM).
Methods:  A  total of 98  consecutive  patients  with  HCM  (71.4%  males;  mean  age  51.18  ± 15.47 years)
between  2012  and  2013  were  evaluated  by measuring  the level  of  serum  hs-cTnT  along  with  other
clinical  assessments.
Results: There  were  42  (42.9%)  patients  with  a minimum  serum  hs-cTnT  level  of  14  ng/L.  The  mean  hs-cTnT
level  was  12.37  ng/L (6.94–24.26  ng/L).  There  were  signiﬁcant  differences  in chest  pain  New  York  Heart
Association  functional  class,  left  ventricular  hypertrophy  in  the  surface  electrocardiogram,  non-sustained
ventricular  tachycardia  in  24-h  electrocardiogram-Holter  monitoring,  left  atrial  (LA)  area  index,  ratio  of
peak  early  (E) transmitral  ﬁlling  velocity  to peak early  diastolic  annular  velocity  (Ea  septal)  at  the  level  of
the  septal  mitral  annulus  (E/Ea  septal),  maximum  left ventricular  (LV)  wall  thickness  ≥  30 mm,  and  peak
LV  outﬂow  gradient  ≥  30 mmHg  in  echocardiography  between  the  patients  with  hs-cTnT  < 14  ng/L  and
those  with  hs-cTnT  ≥ 14  ng/L.  However,  after  multivariate  analysis,  age, maximum  LV  wall  thickness,  LA
area  index,  and  E/Ea  septal  remained  as the independent  determinants  of elevated  hs-cTnT  in HCM.
Conclusions:  The  results  demonstrated  that  hs-cTnT  was  elevated  in  a signiﬁcant  number  of  our  HCM
patients;  therefore,  hs-cTnT  can  be introduced  as a valuable  marker  of  myocardial  injury  in HCM  patients.
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Hypertrophic cardiomyopathy (HCM) has been generally
eﬁned as an unexplained hypertrophied non-dilated left ventri-
le in the absence of any other cardiac or systemic disease [1].
longside a marked heterogeneity in clinical expression and prog-
osis, unexpected sudden cardiac death in all ages, especially young
eople, is the most important component of its natural history,
endering HCM a dilemma to clinicians and cardiovascular special-
sts. Other complications linked to higher mortality or morbidity
n HCM are progressive heart failure and atrial ﬁbrillation (AF),
eading to embolic stroke [2,3]. However, despite the different
arkers that are associated with myocardial ischemia and injury,
here are only a few reliable biomarkers for the clinical assessment
nd prediction of events in HCM patients. In this regard, high-
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sensitivity cardiac troponin T (hs-cTnT) might be useful for risk
stratiﬁcation and predicting adverse cardiovascular events in HCM
patients.
Cardiac troponin and its certain subtypes are currently the
markers of choice because of their tissue speciﬁcity and sen-
sitivity. Serum concentration of hs-cTnT is a novel and highly
sensitive and speciﬁc marker of myocyte injury and can detect
concentrations signiﬁcantly lower than 99th percentile of the
normal reference population [2,4]. Indeed, hs-cTnT is a reliable
indicator of subclinical or ongoing myocardial damage. Never-
theless, there are several conditions other than acute myocardial
infarction which could result in elevated hs-cTnT levels. These
properties of hs-cTnT have prompted endeavors to seek more opti-
mal  screening or management of different myocardial problems
[4,5] and HCM should be regarded as a differential diagnosis in
patients with raised hs-cTnT in the absence of coronary artery
stenosis.
Given the relative paucity of data on the prevalence and deter-
minants of increased hs-cTnT in HCM, we  aimed to evaluate this
marker of cardiac injury in patients with HCM.
vier Ltd. All rights reserved.
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One hundred ten consecutive patients, who  had established
CM diagnosis and were admitted between 2012 and 2013 to
he Outpatient Clinic of Tehran Heart Center, were included
n the present study. All patients were clinically evaluated for
schemic heart disease, of which sixty-ﬁve were suspected to have
oronary artery disease (CAD) and underwent coronary angiog-
aphy. Finally, 12 patients were excluded because of evidence
f signiﬁcant CAD in coronary angiography. The patients were
valuated through medical history, clinical examination, 12-lead
lectrocardiography (ECG), M-mode and two-dimensional Doppler
chocardiography performed by an experienced echocardiogra-
her, and 24-h ECG-Holter monitoring on the same day. The
xclusion criteria consisted of recent established acute coronary
yndrome, creatinine > 1.5 mg/dL, and evidence of ischemic heart
isease.
Variables in medical history included gender, age, dyspnea,
xertional chest pain, cigarette smoking, diabetes, hypertension,
yperlipidemia, history of syncope and aborted sudden cardiac
eath, and family history of HCM or sudden cardiac death. Recorded
ndings of the ECG comprised AF, left ventricular hypertrophy
LVH) based on the precordial voltage criteria of Sokolow and
yon [6], pathologic Q-wave (≥0.04 s duration), and QRS duration.
dditionally, 24-h ECG-Holter monitoring was performed to regis-
er non-sustained ventricular tachycardia (NSVT), deﬁned as three
r more beats ≥120 bpm on ambulatory (Holter) ECG. Echocar-
iographic parameters comprised left ventricular ejection fraction
LVEF), left atrial (LA) area, maximum LV wall thickness, left ven-
ricular outﬂow tract (LVOT) gradient, E-wave, and E/Ea septal
see below). LVEF was determined from apical two-chamber and
our-chamber views via the Simpson biplane method. Systolic dys-
unction was deﬁned as LVEF below a cut-off point of 50%. LA area
as measured by planimetry using apical four-chamber view and
as indexed to the body surface area. LVOT gradient was  calcu-
ated from continuous-wave Doppler using the simpliﬁed Bernoulli
quation with a cut-off point ≥30 mmHg  at rest. Peak early (E)
ransmitral ﬁlling velocity and peak early diastolic annular velocity
t the level of the septal mitral annulus (E/Ea septal) were mea-
ured, and E/Ea septal ratio was calculated. The criteria for the
iagnosis of HCM were LV wall thickness ≥15 mm without any
ther cardiac or systemic disease capable of begetting LVH [1].
ased on the morphologic and hemodynamic ﬁndings in echocar-
iography, HCM was classiﬁed into the three subgroups of (1) HCM
ith obstruction (presence of a basal LVOT obstruction gradient
30 mmHg  at rest), (2) HCM without obstruction, and (3) apical
CM characterized as hypertrophy predominantly involving the
V apex on echocardiography and giant negative T waves on the
CG.
In order to evaluate the serum hs-cTnT level and its association
ith clinical factors, the patients were divided into two  groups:
hose with a serum hs-cTnT level < 14 ng/L and those with a serum
s-cTnT level ≥14 ng/L.
Blood samples were collected at the time of clinical evaluation.
he test was repeated 24 h later in the patients having attended
or 24-h ECG-Holter monitoring (n = 73). There was no signiﬁcant
ifference between the two values (correlation = 99.4%), and the
rst value for hs-cTnT was used for analysis. The plasma samples
ere centrifuged at 15 000 rpm for 10 min. Serum levels of hs-cTnT
ere assayed with the Elecsys 2010 analyzer (Roche Diagnostics,
asel, Switzerland) using electrochemiluminescence according to
he manufacturers’ instructions. The inter-assay variations for the
etermination of normal and abnormally high levels of hs-cTnT
ere 5.3% and 2.4%, respectively, and the intra-assay variations for
he determination of normal and abnormally high levels of hs-cTnT
ere 3.6% and 2.2%, respectively, with a lower detection limit oflogy 63 (2014) 140–144 141
3 ng/L. The cut-off value for hs-cTnT by a reference interval of 99%
was 14 ng/L.
Informed consent was obtained from all the patients, and the
study was approved by the Ethics Committee of Tehran Heart Cen-
ter and the Committee of Medical Ethics of Tehran University of
Medical Sciences.
The continuous variables are expressed as mean ± standard
deviation or median (interquartile range), and they were compared
between the patients with hs-cTnT ≥14 ng/L and those with hs-
cTnT < 14 ng/L using the Student t-test or the Mann–Whitney U
test. The categorical variables are presented as frequencies and
percentages, and they were compared between the two above-
mentioned groups (hs-cTnT ≥14 ng/L vs. hs-cTnT <14 ng/L) using
the chi-square or the Fisher exact test. The multiple logistic regres-
sion model with the backward elimination method was employed
to determine the predictors of elevated hs-cTnT (≥14 ng/L).
Variables with a p-value less than 0.2 in the univariate anal-
ysis were included in the multivariable model. The effects of the
independent predictors of elevated hs-cTnT in the ﬁnal model
were expressed as odds ratios (OR) with 95% conﬁdence intervals.
Model calibration was  estimated using the Hosmer–Lemeshow
goodness-of-ﬁt statistic (p-value = 0.851). Model discrimination
was measured using the c statistic, which is equal to the area under
the ROC (Receiver Operating Characteristic) curve. The statistical
software SPSS (version 15.0) for Windows (SPSS Inc., Chicago, IL,
USA) was used.
Results
Having excluded 12 patients with evidence of CAD, we studied
98 eligible patients, comprising 70 (71.4%) males and 28 (28.6%)
females with a mean age of 51.18 ± 15.47 years. There were 42
(42.9%) patients with serum hs-cTnT levels of ≥14 ng/L. The median
for the hs-cTnT level was  12.37 ng/L (6.94–24.26 ng/L). There were
6 patients with hs-cTnT levels below the detection limit of 3 ng/L;
two of these patients had apical HCM.
The baseline demographic and echocardiographic characteris-
tics of the participants are depicted in Table 1. The frequency of
hs-cTnT ≥ 14 ng/L among the patients with a history of cigarette
smoking was 7.1%, as opposed to 21.4% in the patients with hs-
cTnT < 14 ng/L (p = 0.052). The frequency of hs-cTnT ≥ 14 ng/L in the
patients with a diabetes history was 11.9%, in comparison with 8.9%
in those with hs-cTnT < 14 ng/L (p = 0.741). Also, the frequency of
hs-cTnT ≥ 14 ng/L was 21.45% in the patients with hyperlipidemia,
in comparison to 14.3% in those with hs-cTnT < 14 ng/L (p = 0.355).
The univariate association between the variables and the serum
level of hs-cTnT is summarized in Table 2. The serum hs-cTnT values
were not signiﬁcantly different between the patients with exer-
tional dyspnea with different NYHA functional classes (p = 0.247).
There was  a low association between hs-cTnT values and AF
(p = 0.098). Among the patients with a history of syncope, 43.47%
had serum hs-cTnT levels ≥ 14 ng/L (p = 0.945). Sixteen (57.14%)
patients with a family history of sudden cardiac death exhib-
ited abnormal hs-cTnT levels (p = 0.071). In 70.0% of the patients
with NSVT on 24-h ECG-Holter monitoring, the hs-cTnT level was
≥14 ng/L (p = 0.003). A number of patients (n = 25) did not agree to
undergo ECG-Holter monitoring. Among the patients with signif-
icant LV wall thickness ≥30 mm,  62.5% showed hs-cTnT ≥14 ng/L
(p = 0.083).
No signiﬁcant difference was found between the subtypes of
apical HCM, hypertrophic obstructive cardiomyopathy, and HCM
without obstruction and abnormal hs-cTnT levels (p = 0.151). There
were signiﬁcant differences in chest pain NYHA functional class,
LVH in the ECG, NSVT in 24-h ECG-Holter monitoring, LA area
index, maximum LV wall thickness ≥30 mm,  and peak LVOT
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Table  1
Demographic data of the study population.
Variables Patients (n = 98)
Gender: male 70 (71.4%)
Age, years 51.18 ± 15.47
Dyspnea on exertion (NYHA)
FC I 28 (28.6%)
FC II 61 (62.2%)
FC III 9 (9.2%)
Chest pain on exertion (NYHA)
FC I 65 (66.3%)
FC II 28 (28.6%)
FC III 5 (5.1%)
Syncope history 23 (23.5%)
Aborted SCD 1 (1%)
Family history of HCM 39 (39.8%)
Family history of SCD 28 (28.6%)
hs-cTnT (ng/L) 12.37 (6.94–24.26)
hs-cTnT ≥ 14 ng/L 42 (42.9%)
ECG
LVH 72 (73.5%)
Q  Wave 19 (19.4%)
QRS Duration 108.00 (94.00–128.00)
AF  6 (6.1%)
Twenty-four-hour ECG-Holter monitoring (n = 73)
NSVT 20 (27.4%)
Echocardiography
EF  (%) 60.00 (55.00–60.00)
Apical HCM 7 (7.1%)
HOCM 21 (21.4%)
HCM without obstruction 70 (71.42%)
Maximum LV wall thickness (≥30 mm)  16 (16.3%)
LA area index 11.78 (10.69–14.84)
MR  Severity
Mild 55 (59.1%)
Moderate 18 (19.4%)
Severe 8 (8.7%)
Peak LVOT gradient at rest (≥30 mmHg) 22 (22.4%)
E/Ea septal 17.68 (12.56–25.15)
AF, atrial ﬁbrillation; ECG, electrocardiography; EF, ejection fraction; HOCM,
hypertrophic obstructive cardiomyopathy; FC, functional class; HCM, hypertrophic
cardiomyopathy; hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrium; LV,
left  ventricular; LVH, left ventricular hypertrophy; LVOT, left ventricular outﬂow
tract; MR, mitral regurgitation; NSVT, non-sustained ventricular tachycardia; NYHA,
New York Heart Association; SCD, sudden cardiac death.
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Table 2
Univariate association between variables and serum levels of hs-cTnT.
Variable hs-cTnT(n = 56)
< 14 ng/L
hs-cTnT
(n = 42)
≥14 ng/L
p-Value
Male (n = 70) 41 (73.2%) 29 (69.0%) 0.651
Female (n = 28) 15 (26.8%) 13 (31.0%) 0.052
Age  (years) 49.05 ± 14.49 54.02 ± 16.44 0.116
Dyspnea (NYHA) 0.861
FC  I (n = 28) 16 (28.6%) 12 (28.6%)
FC II (n = 61) 34 (60.7%) 27 (64.3%)
FC III (n = 9) 6 (10.7%) 3 (7.1%)
Chest pain (NYHA) 0.043
FC  I (n = 65) 39 (69.6%) 26 (61.9%)
FC II (n = 28) 12 (21.4%) 16 (38.1%)
FC III (n = 5) 5 (8.9%) 0 (0.0%)
Syncope history 13 (23.2%) 10 (23.8%) 0.945
Aborted SCD 1 (1.8%) 0 (0.0%) 0.999
Family history of SCD 12 (21.4%) 16 (38.1%) 0.071
ECG
LVH 36 (64.3%) 36 (85.7%) 0.017
Q  wave 9 (16.15%) 10 (23.8%) 0.388
QRS duration 111.37 ± 24.75 117.20 ± 29.91 0.325
AF  1 (1.8%) 5 (11.9%) 0.081
Twenty-four-hour 24-hour ECG-Holter monitoring (n = 73)
NSVT 6 (14.3%) 14 (45.25%) 0.003
Echocardiography
EF  (%) 57.39 ± 7.36 58.07 ± 7.07 0.621
Apical HCM 6 (10.7%) 1 (2.4%) 0.233
HOCM 9 (16.1%) 12 (28.6%) 0.136
HCM without obstruction
LA area index 11.88 ± 2.36 13.83 ± 2.89 0.001
Maximum LV wall
thickness (≥30)
20.55 ± 6.88 24.90 ± 6.79 0.002
MR severity (n = 93) 0.281
Mild 32 (61.4%) 23 (56.1%)
Moderate 7 (13.5%) 11 (26.8%)
Severe 4 (7.7%) 4 (9.8%)
Peak LVOT gradient
(≥30 mmHg)
19.10 ± 30.03 26.35 ± 28.14 0.024
E/Ea septal 17.63 ± 8.95 25.75 ± 15.44 0.001
AF, atrial ﬁbrillation; ECG, electrocardiography; EF, ejection fraction; HOCM,
hypertrophic obstructive cardiomyopathy; FC, functional class; HCM,  hypertrophic
cardiomyopathy; hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrium; LV,
left ventricular; LVH, left ventricular hypertrophy; LVOT, left ventricular outﬂow
control group but relatively lower than the values in acute coronary
events. Likewise, we found that 42.9% of our patients had increased
hs-cTnT levels.
Table 3
Multivariable predictors of the serum level of hs-cTnT.
Variable Odds ratio (95% conﬁdence interval) p-Value
Age 1.071 (1.021–1.123) 0.005
LA  area index 1.188 (0.972–1.453) 0.093
Maximum LV thickness 1.184 (1.049–1.337) 0.006
E/Ea  septal 1.046 (0.994–1.100) 0.083ata are shown as numbers (percent), mean ± SD, or medians (Inter Quartile Range).
ut-off point for hs-cTnT = 14 ng/L.
radient ≥30 mmHg  between the two groups of patients with hs-
TnT < 14 ng/L and those with hs-cTnT ≥ 14 ng/L (Table 2). Finally,
ge, maximum LV wall thickness, LA area index, and E/Ea septal
ere determined as the independent predictors of elevated hs-
TnT in HCM (Table 3).
iscussion
In the present study, we assessed the prevalence and determi-
ants of elevated hs-cTnT in patients with HCM. This assessment
evealed that a signiﬁcant number of our HCM patients (42.9%)
ad increased levels of hs-cTnT (≥14 ng/L). In addition, age, LA
rea index, maximum LV wall thickness, and E/Ea septal were the
ndependent determinants of elevated hs-cTnT.
Cardiac troponins are sensitive and speciﬁc biomarkers for the
iagnosis of acute myocardial infarction. Today, hs-cTnT serum
oncentration is a novel and highly sensitive and speciﬁc marker
or the detection of concentrations signiﬁcantly lower than 99th
ercentile of the normal reference population [2,4]. There are, how-
ver, several conditions other than myocardial infarction which can
ead to troponin release; these conditions are attributed to myocar-
ial injury. It is, therefore, important to distinguish acute causes of
Tn elevation (e.g. acute myocardial infarction) from chronic ele-
ations [7]. We  found that hs-cTnT was elevated in a signiﬁcanttract; MR,  mitral regurgitation; NSVT, non-sustained ventricular tachycardia; NYHA,
New York Heart Association; SCD, sudden cardiac death.
portion of our patients, who were diagnosed with HCM with no
evidence of CAD, and there was  no signiﬁcant change in these val-
ues when the measurements were repeated after 24 h. This chronic
elevation of hs-cTnT in stable HCM patients may  help to identify a
larger number of HCM patients with ongoing myocyte injury.
There are only a few studies in the existing literature that have
reported increased levels of cTn in patients with HCM [8–10].
Moreno et al. [10] showed high levels of hs-cTnT in up to 42% of
stable HCM patients; these levels were higher than those in theHosmer–Lemeshow goodness-of-ﬁt statistics = 4.071; degree of freedom = 8;
p  = 0.851; logistic regression analyses (n = 98 patients). Cut-off point for hs-cTnT was
14 ng/L. Area under the curve: 0.840 (0.758–0.921); p = 0.001.
hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrium; LV, left ventricular.
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Maximum LV wall thickness, as an important marker associated
ith sudden cardiac death and LV systolic dysfunction deterio-
ation in HCM [11–13], had a signiﬁcant association with cardiac
roponin I (cTnI) and hs-cTnT levels in two previous studies [10,13].
e also found a signiﬁcant association between maximum LV wall
hickness and hs-cTnT levels in our multivariate analyses.
A major pathophysiologic abnormality in HCM is diastolic dys-
unction, which can be assessed by LA size or E/Ea septal. LA
emodeling is allied to greater LV hypertrophy, more diastolic
ysfunction, higher ﬁlling pressures, and higher risk of atrial
rrhythmias [14]. In the Kubo et al. study [13], an independent asso-
iation between cTnI and E/Ea septal was reported. Moreno et al.
10] also reported a signiﬁcant correlation between cTnT values and
A diameter and E/Ea septal. In agreement with these studies, our
ultivariate analysis showed that LA area index and E/Ea septal
ere signiﬁcantly correlated with hs-cTnT levels.
ECG-Holter monitoring plays a major role in the detection
f ventricular tachyarrhythmias and risk stratiﬁcation of asymp-
omatic or symptomatic patients with HCM in as much as the
pisodes of NSVT can identify patients at higher risk for sudden
ardiac death [15]. Moreno et al. [10] did not ﬁnd any signiﬁcant
ssociation between NSVT and hs-cTnT levels. In our study, how-
ver, although there was a signiﬁcant association between NSVT
nd hs-cTnT in univariate analysis, there was no signiﬁcant associ-
tion between these two values in the multivariate analysis.
We found no signiﬁcant association between hs-cTnT levels and
VEF or AF rhythm. There was only a trend for the patients with
F rhythm to have elevated hs-cTnT values. Nonetheless, previous
tudies suggested a signiﬁcant association between these variables
nd hs-cTnT levels [10,13,16]. This incompatibility could be due
o the small number of patients with LV systolic dysfunction (7
atients) or AF rhythm (6 patients) in our population study.
Age was not associated signiﬁcantly with cTn levels in some
tudies [10,13]. In contrast, we found a signiﬁcant correlation
etween increased age in our HCM patients and hs-TnT levels. This
ssociation was also found in a recent study by Kubo et al. [16].
Kubo et al. [16] revealed that the hs-cTnT level was an indepen-
ent predictor of cardiovascular events in patients with HCM. Of
igniﬁcant note, the authors also reported that higher levels of hs-
TnT values were associated with greater risk. These ﬁndings have
agniﬁed the importance of the measurement of hs-cTnT levels
n patients with HCM in the prediction of the prognosis in these
atients [16].
Information regarding the precise mechanism and pathology of
levation in serum cTnT is unresolved. A study by Hessel et al.
howed stretch-related mechanism of cTn release mediated by
ntegrin [17,18]. In heart failure, an increased myocardial wall stress
nd LV end-diastolic pressure has been suggested as a leading
ause of decrease in the subendocardial perfusion, and increase the
oncentration of cTn [17,19]. There are several studies that have
emonstrated reduced myocardial perfusion, insufﬁcient hypop-
rfusion, and myocardial ﬁbrosis in HCM patients by magnetic
esonance imaging [16,20–26]. It seems that inappropriate hyper-
rophy of the myocardium and therefore discrepancy between
yocardial demand and coronary arterial supply is the probable
athologic mechanism of myocyte injury and therefore hs-cTnT
elease in HCM patients [16].
The present study merits due attention on account of its uti-
izing hs-cTnT as a novel cardiac speciﬁc marker in HCM patients.
oreover, our results revealed stable serum hs-cTnT levels; this
s an issue that was not addressed in previous studies. There
re, however, limitations to our study, ﬁrst and foremost among
hich are its small sample size and its cross-sectional design with
heir inherent disadvantages. Another drawback of signiﬁcance is
hat our study was a single-center one. We  would suggest that
urther studies be conducted in larger populations in order to
[logy 63 (2014) 140–144 143
determine deﬁnitely the clinical value and determinants of hs-
cTnT.
Conclusion
The results of the current study, conducted on patients with
HCM, demonstrated that hs-cTnT was stably elevated in a signif-
icant proportion of the study population. In addition, age, LA area
index, maximum LV wall thickness, and E/Ea septal were identi-
ﬁed as the independent determinants of elevated hs-cTnT in our
patients with HCM. It seems that the hs-cTnT serum level can
be introduced as a valuable marker of myocardial injury in HCM
patients.
Conﬂict of interest
The authors report no conﬂict of interest.
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